Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Mesoblast Limited (MESO) Price & Performance

VanEck JP Morgan EM Local Currency Bond ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

VanEck JP Morgan EM Local Currency Bond ETF vs Mesoblast Limited — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.47, while Mesoblast Limited trades at $18.53 (market cap $2.31B). The key difference: Mesoblast Limited is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.

EMLCMESO
Sector
Fixed IncomeTechnology
52-Week High
$26.59$20.96
52-Week Low
$24.83$11.35
Market Cap
$2.31B
Enterprise Value
$2.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck JP Morgan EM Local Currency Bond ETF

EMLC trades at $25.47 with minimal daily movement (-0.06%). Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share quarterly, providing income stability. Recent news highlights growing institutional interest in emerging market debt as investors seek yield above Treasury bonds.

The outlook remains positive given the 6.1% yield advantage over Treasuries, though currency risk and capital erosion concerns persist. Short interest has surged 73% recently, indicating some skepticism about sustainability. Federal Reserve policy decisions will be crucial for EM debt performance through 2026.

Mesoblast Limited

MESO is trading at $18.61, up 11.17% today, with strong technical momentum as moving averages signal bullish conditions. The company shows promising revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a -144.33% net income margin. Recent milestones include completing patient recruitment for a Phase 3 chronic low back pain trial and securing a $50 million non-dilutive facility.

The outlook is cautiously optimistic given strong analyst support (45% buy ratings) and commercial progress, but significant execution risks remain. Investors face high valuation multiples (P/S 30.52) and substantial cash burn despite reduced operating expenses. The stock's near-term direction will depend on clinical trial outcomes and revenue acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck JP Morgan EM Local Currency Bond ETF

EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.

Read more on EMLC

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO